Logo image of BGBIO.OL

BERGENBIO ASA (BGBIO.OL) Stock Price, Quote, News and Overview

OSL:BGBIO - Euronext Oslo - NO0013251173 - Common Stock - Currency: NOK

1.93  0 (0%)

BGBIO.OL Quote, Performance and Key Statistics

BERGENBIO ASA

OSL:BGBIO (5/28/2025, 7:00:00 PM)

1.93

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High15.67
52 Week Low1.45
Market Cap75.44M
Shares39.09M
Float22.24M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-20 2025-08-20
IPO04-07 2017-04-07


BGBIO.OL short term performance overview.The bars show the price performance of BGBIO.OL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60 -80

BGBIO.OL long term performance overview.The bars show the price performance of BGBIO.OL in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 200 400

The current stock price of BGBIO.OL is 1.93 NOK. In the past month the price increased by 9.41%. In the past year, price decreased by -86.38%.

BERGENBIO ASA / BGBIO Daily stock chart

BGBIO.OL Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 17.88 286.51B
AMG.DE AMGEN INC 13.57 133.86B
GIS.DE GILEAD SCIENCES INC 13.98 118.91B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 102.00B
1REGN.MI REGENERON PHARMACEUTICALS 13.77 58.22B
ARGX.BR ARGENX SE 108.46 31.32B
22UA.DE BIONTECH SE-ADR N/A 21.05B
IDP.DE BIOGEN INC 8.2 16.80B
1BMRN.MI BIOMARIN PHARMACEUTICAL INC 33.78 9.98B
0QF.DE MODERNA INC N/A 9.23B
1MRNA.MI MODERNA INC N/A 9.15B
BIO.DE BIOTEST AG 65.85 1.69B

About BGBIO.OL

Company Profile

BGBIO logo image BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Bergen, Hordaland and currently employs 15 full-time employees. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The firm's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.

Company Info

BERGENBIO ASA

Mollendalsbakken 9

Bergen HORDALAND NO

Employees: 14

BGBIO Company Website

BGBIO Investor Relations

Phone: 4755961159

BERGENBIO ASA / BGBIO.OL FAQ

What is the stock price of BERGENBIO ASA today?

The current stock price of BGBIO.OL is 1.93 NOK.


What is the ticker symbol for BERGENBIO ASA stock?

The exchange symbol of BERGENBIO ASA is BGBIO and it is listed on the Euronext Oslo exchange.


On which exchange is BGBIO.OL stock listed?

BGBIO.OL stock is listed on the Euronext Oslo exchange.


What is the price forecast or stock price prediction for BERGENBIO ASA stock?

7 analysts have analysed BGBIO.OL and the average price target is 5.1 NOK. This implies a price increase of 164.25% is expected in the next year compared to the current price of 1.93. Check the BERGENBIO ASA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BERGENBIO ASA worth?

BERGENBIO ASA (BGBIO.OL) has a market capitalization of 75.44M NOK. This makes BGBIO.OL a Micro Cap stock.


How many employees does BERGENBIO ASA have?

BERGENBIO ASA (BGBIO.OL) currently has 14 employees.


What are the support and resistance levels for BERGENBIO ASA (BGBIO.OL) stock?

BERGENBIO ASA (BGBIO.OL) has a support level at 1.76 and a resistance level at 1.94. Check the full technical report for a detailed analysis of BGBIO.OL support and resistance levels.


Is BERGENBIO ASA (BGBIO.OL) expected to grow?

The Revenue of BERGENBIO ASA (BGBIO.OL) is expected to decline by -100% in the next year. Check the estimates tab for more information on the BGBIO.OL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BERGENBIO ASA (BGBIO.OL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BERGENBIO ASA (BGBIO.OL) stock pay dividends?

BGBIO.OL does not pay a dividend.


When does BERGENBIO ASA (BGBIO.OL) report earnings?

BERGENBIO ASA (BGBIO.OL) will report earnings on 2025-08-20.


What is the Price/Earnings (PE) ratio of BERGENBIO ASA (BGBIO.OL)?

BERGENBIO ASA (BGBIO.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.75).


BGBIO.OL Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to BGBIO.OL. When comparing the yearly performance of all stocks, BGBIO.OL is a bad performer in the overall market: 95.62% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BGBIO.OL Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to BGBIO.OL. BGBIO.OL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BGBIO.OL Financial Highlights

Over the last trailing twelve months BGBIO.OL reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS decreased by -125.07% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -89.4%
ROE -113.51%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%63.5%
Sales Q2Q%92.37%
EPS 1Y (TTM)-125.07%
Revenue 1Y (TTM)139.55%

BGBIO.OL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 40% to BGBIO.OL. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 17.6% and a revenue growth -100% for BGBIO.OL


Ownership
Inst Owners4.19%
Ins Owners3.45%
Short Float %N/A
Short RatioN/A
Analysts
Analysts40
Price Target5.1 (164.25%)
EPS Next Y17.6%
Revenue Next Year-100%